Patents by Inventor Peter G. Bundesen

Peter G. Bundesen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5591572
    Abstract: The invention provides peptides having immunological properties in common with the backbone of an immunodominant region of the transmembrane envelope protein of mammalian immunodeficiency viruses, which region comprises a disulphide loop and which region is unexpectedly highly conserved in mammalian immunodeficiency viruses derived from different mammalian sources. The invention also provides method and immunoassay test kits for detection of mammalian immunodeficiency viruses using these above peptides. The invention also relates to antibodies directed against the above peptides, and their use in immunoassays and as immunoadsorbents for mammalian immunodeficiency virus.
    Type: Grant
    Filed: February 24, 1994
    Date of Patent: January 7, 1997
    Assignees: St. Vincents Institute of Medical Research Limited, Agen Limited
    Inventors: Bruce E. Kemp, Carmel J. Hillyard, Dennis B. Rylatt, Peter G. Bundesen
  • Patent number: 5413913
    Abstract: In an erythrocyte agglutination assay, the agglutination reagent comprises at least one erythrocyte binding molecule coupled to at least one specific analyte binding molecule wherein the erythrocyte binding molecule does not cause agglutination when incubated with erythrocytes in the absence of analyte (in the case of a direct assay) or analyte binding reagent (in the case of an indirect assay). Preferably, the erythrocytes are endogenous to the blood sample to be tested, that is, a whole blood sample is assayed. Mixtures of conjugates and conjugates of analyte analogues with erythrocyte binding molecules may also be used as agglutination reagents. The reagents and their use in direct or indirect assays is disclosed.
    Type: Grant
    Filed: February 3, 1994
    Date of Patent: May 9, 1995
    Assignee: Agen Biomedical, Ltd.
    Inventors: Carmel J. Hillyard, Dennis B. Rylatt, Bruce E. Kemp, Peter G. Bundesen
  • Patent number: 5086002
    Abstract: In a novel, erythrocyte agglutination assay, the agglutination reagent comprises at least one erythrocyte binding molecule coupled to at least one specific analyte binding molecule wherein the erythrocyte binding molecule does not cause agglutination when incubated with erythrocytes in the absence of analyte (in the case of a direct assay) or analyte binding reagent (in the case of an indirect assay). Preferably, the erythrocytes are endogenous to the blood sample to be tested, that is, a whole blood sample is assayed. Mixtures of conjugates and conjugates of analyte analogues with erythrocyte binding molecules may also be used as agglutination reagents. The reagents and their use in direct or indirect assays is disclosed.
    Type: Grant
    Filed: March 16, 1989
    Date of Patent: February 4, 1992
    Assignee: Agen Biomedical, Ltd.
    Inventors: Carmel J. Hillyard, Dennis B. Rylatt, Bruce E. Kemp, Peter G. Bundesen
  • Patent number: 4894347
    Abstract: In an erythrocyte agglutination assay, the agglutination reagent comprises at least one erythrocyte binding molecule coupled to at least one specific analyte binding molecule wherein the erythrocyte binding molecule does not cause agglutination when incubated with erythrocytes in the absence of analyte. Preferably, the erythrocytes are endogenous to the blood sample to be tested, that is, a whole blood sample is assayed. Mixtures of conjugates and conjugates of analyte analogues with erythrocyte binding molecules may also be used as agglutination reagents. The reagents and their use in direct or indirect assays is disclosed.
    Type: Grant
    Filed: January 13, 1988
    Date of Patent: January 16, 1990
    Assignee: Agen Limited
    Inventors: Carmel J. Hillyard, Dennis B. Rylatt, Bruce E. Kemp, Peter G. Bundesen
  • Patent number: 4758524
    Abstract: The invention relates to a method of a preparation of monoclonal antibody derived from a crosslinked fibrin derivative including the steps of:(i) obtaining a crosslinked fibrin derivative or extract containing same; and(ii) forming an antibody to said derivative or extract by cloning antibody producing cells from an animal having been administered thereto said derivative or extract.A screening assay for use in the abovementioned method which includes the steps of:(A) coating a surface with an antigen selected from a(i) crosslinked fibrin derivative;(ii) extract containing said derivative; or(iii) fibrinogen degradation product.
    Type: Grant
    Filed: March 15, 1984
    Date of Patent: July 19, 1988
    Assignee: Fielder Gillespie David Limited
    Inventors: Peter G. Bundesen, Dennis B. Rylatt